Radiofrequency ablation (RFA) is an effective and real-time targeting modality for small hepatocellular carcinomas (HCCs). However, mistargeting may occur when the target tumor is confused with cirrhotic nodules or because of the poor conspicuity of the index tumor under ultrasonography (US). Real-time virtual sonography (RVS) can provide the same reconstruction computed tomography images as US images. The aim of this study is to investigate the usefulness of RVS-assisted RFA for HCCs that are inconspicuous or conspicuous under US. A total of 21 patients with 28 HCC tumorsddivided into US inconspicuous and high-risk subgroup (3 tumors in 3 patients), US inconspicuous and nonhigh-risk subgroup (5 tumors in 4 patients), US conspicuous and high-risk subgroup (16 tumors in 14 patients), and US conspicuous and nonhigh-risk subgroup (4 tumors in 3 patients)dunderwent RVS-assisted RFA between May 2012 and June 2014 in our institution. The mean diameter of the nodules was 2.0 AE 1.1 cm. The results showed that the complete ablation rate is 87.5% (7/8) in the US undetectable group and 75% (15/20) in the US detectable group. A comparison between six tumors with incomplete ablation and 22 tumors with complete ablation showed higher alpha-fetoprotein level (mean, 1912 ng/mL vs. 112 ng/mL) and larger tumor size (mean diameter, 26 mm vs. 16 mm) in the incomplete ablation nodules (both p < 0.05). In conclusion, RVSassisted RFA is useful for tumors that are difficult to detect under conventional US and may
Introduction
Hepatocellular carcinomas (HCCs) are one of the most common malignancies and major causes of mortality worldwide [1e3] . Treatment for HCCs depends on the tumor stage and liver function. Locoregional treatments, including percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA), have been considered effective modalities for small HCCs [4e6] . Of these, percutaneous ultrasonography (US)-guided RFA is an effective, fast, and real-time targeting modality for small HCCs [5e7]. However, mistargeting may occur for several reasons: when the target tumor is confused with cirrhotic nodules; poor conspicuity of the index tumor under US [8e10]; safety concerns during repeat RF electrode placement for tumors in high-risk locations, which are close to the hepatic capsule, vital organs, vessels, or central bile ducts [7e9]. Real-time virtual sonography (RVS) can provide the same multiplanar reconstruction computed tomography (CT) or magnetic resonance images as US images under real-time US monitor screen. Some studies have shown the usefulness of RVS-assisted local treatment of HCCs that are poorly detected by conventional US, but so far no study has been conducted in terms of RVS-assisted RFA for HCCs in high-risk locations [7, 11, 12] . The aim of this study is to investigate the efficacy of RVS-assisted RFA for HCCs that are inconspicuous on conventional US or are situated in high-risk locations.
Materials and methods

Patients
In this retrospective study, we reviewed the prospective records of consecutive patients with HCC treated with RVS-guided RFA in our department between May 2012 and June 2014. All index HCCs were diagnosed by cytology, pathology, or according to the criteria of the American Association for the Study of Liver Disease [6] . All patients had cirrhosis with ChildePugh class A or B. None of them have extrahepatic metastasis or intrahepatic vessel invasion. Impaired coagulopathy was required to be corrected prior to the treatment (prothrombin time < 3 seconds, platelet concentration > 50,000 cells/mm 3 ). All patients received RFA after a comprehensive discussion during our HCC multidisciplinary meeting. Informed consent was obtained from each patient prior to the treatment. This study was approved by the Institutional Review Board, Linkuo Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Study design
A total of 23 patients diagnosed with HCC were treated with RVS-guided RFA in our department between May 2012 and June 2014. All patients have HCC nodules that are either inconspicuous under conventional US or in high-risk locations but can be clearly depicted under dynamic CT. A detectable lesion under conventional US was defined as a lesion where the margin and echogenicity of the index tumor are visible, whereas an undetectable lesion is one in which the margin and echogenicity of index tumor are not visible. The high-risk locations were defined as < 5 mm from the liver capsule, a large vessel, or an extrahepatic vital organ. Patients with more than three nodules were excluded from this study and might receive other types of treatment, such as transarterial chemoembolization (TACE). Patients with a follow-up of at least 3 months after treatment were enrolled in this study. To evaluate the effects of RVS-guided RFA and to minimize bias, we enrolled only patients who were not undergoing other types of treatment, such as PEI, RFA, or even TACE, within the past 2 months. Two patients were excluded for receiving RFA within 30 days prior to RVS-guided RFA. A total of 28 HCC nodules were retrospectively analyzed in 21 patients (18 males and 3 females, mean age 69.5 years) treated with RVS-guided RFA ( Table 1) .
CT and magnetic resonance imaging protocol
CT or magnetic resonance imaging (MRI) examinations were performed within 1 month prior to RFA using a four-phase method. These four dynamic phases were precontrast, arterial, portal, and delayed. The slice thickness of CT was 5 mm, and the table feed was 5 mm/s. One hundred milliliters of nonionic contrast material [iopamidol (Iopamiron 370); Bayer Yakuhin, Osaka, Japan] at a rate of 3.5 mL/s using a power injector (Nemoto Kyorindo, Tokyo, Japan) was injected into each patient. In the dynamic MR images, arterial and portal phases were obtained after injection of gadoliniumediethylenetriamine pentaacetic acid (gadopentetate dimeglumine) or gadoliniumeethoxybenzyle diethylenetriamine pentaacetic acid (Gd-EOB-DTPA; gadoxetate disodium) [13, 14] . The size of the HCC nodule was determined by either the arterial or portal phase, depending on which phase could best depict the nodule. To assess the treatment effect of RFA, dynamic CT or MRI using 5-mm-slice scans was performed within 1 month after RFA. Those scans were repeated approximately every 3 months if there was no local tumor progression (LTP). LTP was diagnosed if follow-up dynamic CT or MRI revealed a new lesion that had developed close to a previous ablation area [7] .
RVS system
The RVS system comprised an ultrasound scanner, a position sensor unit (EZU-RV3S; Hitachi, Tokyo, Japan; a magnetic sensor unit for RVS), and a computer with RVS software (EZU-RV8; Hitachi). Multiplanar reconstruction images were reconstructed using CT or MRI. The previously acquired CT or MRI data were loaded onto US. The patients were placed in a supine position, with shoulders, buttocks, and heels in contact with the table. While the operator handled realtime US, the ultrasound machine generated multiplanar reconstruction images from the CT volume or MRI data, corresponding to the US images of the same or very similar cross section. The magnetic sensor on the sonography probe precisely captured the magnetic field alternation of the position, direction, or rotation via the transmitter placed at the patient's left flank. Thus, we could mark the target lesion detected on CT/MRI and find some fiducial landmarks (e.g., vessels or organs). Virtual images with marks were revisualized while using conventional US that helped the operator perform RFA.
RFA protocol
Prior to RFA, the three-dimensional anatomical relationships between the target nodules and intrahepatic vessels or vital organs were sufficiently examined, and the distances were measured on RVS. RFA was performed percutaneously under RVS guidance. Straight electrodes with a 3-or 2-cm active tip were used ( Figure 1 ). For enlarging an ablation area, we often used a multiple overlapping ablation technique during the treatment. Artificial ascites or pleural effusion techniques were established when the target nodule was close to the critical organs or located near the hepatic dome [7, 15, 16] . Patients with refractory ascites, portal vein tumor thrombosis, or extrahepatic metastasis were excluded in our study. We only used the automatic mode of RF emission in this study. Radiofrequency energy was delivered for 9e12 minutes in each site [7, 15, 16] . RFA was performed by three experienced hepatologists (C.C. Lin, W.T. Chen, S.M. Lin) who have > 5 years of experience in handling RFA cases in our hospital [4, 17, 18] .
Statistical analyses
Statistical analyses were carried out using the SPSS software, version 20.0 (SPSS Inc., Chicago, IL, USA). Descriptive data with a normal distribution are reported as mean AE standard deviation. Stepwise logistic regression analyses were used to determine the correlation of the predictive factors to clinical outcomes. Student t test and ManneWhitney U test were used to assess the differences between groups in normal-distributed and nonnormaldistributed groups. A two-tailed p < 0.05 was considered statistically significant.
Results
Between May 2012 and June 2014, there were 25 patients with HCCs who have undergone RVS-guided local ablation in our department. Four patients were excluded from this study because two patients underwent RVS-guided PEI, one received TACE therapy, and another patient received RFA within 2 months prior to RVS-guided RFA. Overall, this left us with 21 patients, which comprised 18 males and three females with a total of 28 HCC nodules ( Table 2) . Fifteen patients had a single nodule, five patients had two nodules, and one patient had three nodules. Their mean age was 69.4 (range 57e85) years. All patients were diagnosed with liver cirrhosis via imaging or biopsy. The etiology of underlying diseases included Hepatitis B or Hepatitis C in 19 (90.4%) patients, alcohol consumption in one (4.8%) patient, and cryptogenic etiology in one (4.8%) patient. Twenty patients had ChildePugh A and one patient had ChildePugh B (score Z 7) cirrhosis. The mean diameter of the 28 HCC nodules was 1.9 AE 1.1 (range 0.7e4.5) cm. Among the 28 target lesions, seven nodules were located at the left lobe and the other 21 nodules were in the right lobe. Eight (3 in high-risk group, 5 in nonhigh-risk group) lesions were inconspicuous on conventional US, whereas 20 lesions were conspicuous on conventional US, and of the 28 lesions, 19 (3 inconspicuous and 16 conspicuous) nodules were found in high-risk locations. In the eight HCC nodules inconspicuous by US, six of them were very vague under sonography, and the other two nodules were very close to the previous TACE or RFA site ( Figure 1 ). All eight index tumors (in 8 patients) that were inconspicuous on conventional US had been treated with RFA, PEI, or TACE for other HCC nodules over 2 months prior to RVS-assisted RFA. However, after previous HCC treatments for other HCC nodules, the index tumors remained inconspicuous on conventional US. All the lesions that could not be detected on conventional US could be visualized on CT. They could also be located under RVS. The mean follow-up period was 362 (range 121e817) days. Among the 21 patients, four were treatment-naïve, seven had received RFA only (mean 19.1 months, range 2.3e68 months), and 10 had undergone TACE or TACE plus RFA (mean 9.8 months, range 2.2e20.7 months) prior to RVS-assisted RFA. The RF electrodes were inserted to all 28 HCC nodules with RVS assistance. There were no major complications except in one patient, who had a 4.5-cm tumor at segment 8 near the attached colon at the dome area receiving three placements of RVS-assisted RFA; in this instance, a severe complication developed in the form of pneumoperitoneum due to a thermal injury that was detected 1 day after RFA. A right hemicolectomy was performed to address this setback, and the patient recovered after the operation.
Contrast-enhanced CT was performed within 1 month to evaluate whether complete ablation had been achieved. Twenty-two of the 28 (79%) HCC nodules achieved complete ablation after the first RFA course ( Table 3) . As for the eight target lesions that were inconspicuous on conventional US, seven (87.5%) nodules achieved complete ablation. In the US conspicuous group, 15 (75%) of the 20 tumors achieved complete ablation. A comparison between six tumors with incomplete ablation and 22 tumors with complete ablation showed higher alpha-fetoprotein (AFP; mean, 1912 ng/mL vs. 112 ng/mL) and larger tumor size (mean diameter, 26 mm vs. 16 mm) in the incomplete ablation nodules (both p < 0.05; Table 4 ). Because the AFP level reached 5535 ng/mL in Patient 13 (Table 2) , the AFP level in the US conspicuous group was slightly significantly higher than that in the US inconspicuous group (Table 4 ).
Discussion
Percutaneous US-guided RFA is an accurate and effective curative modality for small HCCs [4e7]. Most small HCCs can be successfully ablated with US-guided RFA; however, for tumors inconspicuous under US but detectable by CT or MRI, US-guided RFA under CT or MRI navigation using the novel RVS device is more feasible and useful.
This issue indicates that in cases where mistargeting may be encountereddsuch as when the target tumor is confused with cirrhotic nodulesdRVS-assisted RFA is a useful option [8e10]. The current results confirm the usefulness of RVS-assisted RFA for tumors undetectable on US. Moreover, concerning the complication after the placement of RF electrodes for tumors in high-risk locations, our study also shows a beneficial result of RVS-assisted RFA for HCCs in these tumors. Concerning the limited effective modalities for tumors in cirrhotic background and high-risk locations, our studydnotwithstanding the fact that it is based on a small sample sizedis still able to provide promising results in terms of effective and safe RFA.
RVS-assisted RFA is a relatively novel device that has been introduced in recent years to treat lesions that are unclear under conventional US. Earlier studies were also based on small sample sizes [8e10,19]; however, these studies had confirmed that RVS assistance can improve the conspicuity of HCCs and the feasibility of percutaneous RFA for HCCs that are not visible on conventional US. In realworld practice, the majority of index tumors are visible on US without RVS assistance. Therefore, we aimed to elucidate the usefulness of RVS-guided RFA for tumors that are inconspicuous on conventional US and/or situated in high-risk locations. Although the sample size is small because this novel device has only been made available recently, our results still showed that RVS-assisted RFA is useful for tumors difficult to detect on conventional US and may be useful for tumors in high-risk locations because it may prevent complications induced by mistargeting.
In the study by Nakai et al. [20] , all 20 enrolled patients with HCCs who underwent RVS-assisted RFA achieved complete ablation, and no local tumor progression was observed during the study period (9e18 months) [10] . However, these patients had single HCC only. In our study, 21 patients with 28 tumors were considered difficult for RFA because majority of these tumors were either in high-risk locations, inconspicuous under conventional US, or both. Of the eight tumors in the US inconspicuous group, the rate of complete ablation after one session of RFA was 87.5% (7 of 8), which was comparable to that of tumors in nonhigh-risk locations after RFA without RVS assistance by indirect comparison with similar study groups [17, 18, 20] . The patient with incomplete ablation underwent a second RFA and achieved complete ablation. No local tumor recurrence was noted after 10 months of follow-up. In the 22 tumors with complete ablation, 13 (59.1%) tumors were in high-risk locations. Moreover, as for the six tumors with incomplete ablation, all of them (100%) were in high-risk locations.
As for ablation-naïve tumors or viable tumors after previous treatment, which are probably undetectable under conventional US, these lesions could always be detected via dynamic CT or MRI, and are thereafter visible in RVS. The operator should evaluate the three-dimensional anatomical relationships between the target tumors and intrahepatic or extrahepatic vasculature, diaphragm, or other landmarks prior to the RFA procedure. The target point of the RFA electrode tip can be marked on the US monitor screen simultaneously; this makes ablation easier to perform because the marks are displayed and the probe can be precisely aimed at the target lesion. After the precise targeting of tumors, RVS-assisted RFA not only achieves a more effective ablation, but can also prevent potential complications after ablation. In this study, only one severe complication was encounteredda patient developed pneumoperitoneum due to colon thermal injury, but this individual recovered after the operation. Based on our study, a satisfactory outcome is achieved with RVS-assisted RFA for tumors undetectable on US. We may therefore expand the utilization of RVS-assisted RFA to HCCs under these situations; although CT-guided RFA can be an alternative to US-guided RFA, the former seems cumbersome and requires a longer procedure time [21] . Although RVS-guided RFA could not greatly improve the technical effectiveness for tumors in high-risk locations, the major complication that ensued was trivial. However, it should be noted that the sample size used in this study was small, and the results were derived from a retrospective analysis. Further study with a larger sample size may be required.
In conclusion, our preliminary results based on a small sample size demonstrate that RVS-assisted RFA is useful for tumors that are difficult to detect on conventional US and may be useful for tumors in high-risk locations because it may prevent complications induced by mistargeting. 
